Search
Padnarsertib
go.drugbank.com/drugs/DB19243InvestigationalSynonyms: Pak4-in-1, 2-propenamide, 3-(6-amino-3-pyridinyl)-n-((5-(4-((4,4-difluoro-1-piperidinyl)carbonyl)phenyl)-7-(4-fluorophenyl)-2-benzofuranyl)methyl)-, (2e)-Categories: Heterocyclic Compounds, 1-RingBenoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.
Synonyms: (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid, 2-(4-chlorophenyl)-α-methyl-5-benzoxazoleacetic acidPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalPalbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. … It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Mixtures: REAMPLA®, REAMPLA®Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexGlyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigational[L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin]. … Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.
Mixtures: SIL - NORBORAL ® 5 MG / 1000 MG, SIL-NORBORAL ® 5/500 MGCategories: Drugs Used in Diabetes, P-glycoprotein inhibitorsPirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigational[A256788] In January 2023, the use of pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy was approved under the FDA's Accelerated … in the presence of Cys481 mutations.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide, 5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2s)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamideDecitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. … It was first marketed under the name Dacogen®.[L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine].
Mixtures: INQOVI (Decitabine 35 mg/Cedazuridine 100 mg) Film-Coated TabletsCategories: Heterocyclic Compounds, 1-RingFormoterol
go.drugbank.com/drugs/DB00983ApprovedInvestigationalFormoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. … [L11256] It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.
Mixtures: FORMODUAL N. 200/6UG, FORMODUAL N. 200/6UGCategories: Cytochrome P-450 Substrates, Adrenergic beta-2 Receptor AgonistsBimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigational[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug … Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form.
Mixtures: BimatoTim-Vision sine 0,3 mg/ml + 5 mg/ml Augentropfen, Lösung im Einzeldosisbehältnis, BEMATORİN-T 0,3 MG + 5 MG/1 ML GÖZ DAMLASI, ÇÖZELTİ, 1 ADETCategories: Cytochrome P-450 Substrates, Prostaglandins F, SyntheticCypCaps
go.drugbank.com/drugs/DB17435ExperimentalSynonyms: Cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphateIrinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigational[L50181, L50186, L50201] Irinotecan liposome was approved by the FDA in February 2024.[L50186] The active metabolite SN-38 is also a potent inhibitor of DNA topoisomerase I. … This leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376]
Categories: Topoisomerase I Inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl, )ethyl)piperidine-1-carboxylate